Risk of new-onset diabetes and efficacy of pharmacological weight loss therapy.

ABSTRACT:

Aims

To develop a clinical risk model to identify individuals at higher risk of developing new-onset diabetes and who might benefit more from weight loss pharmacotherapy.

Materials and methods

A total of 21 143 patients without type 2 diabetes at baseline from two TIMI clinical trials of stable cardiovascular patients were divided into a derivation (~2/3) and validation (~1/3) cohort. The primary outcome was new-onset diabetes. Twenty-seven candidate risk variables were considered, and variable selection was performed using multivariable Cox regression. The final model was evaluated for discrimination and calibration, and for its ability to identify patients who experienced a larger benefit from the weight loss medication lorcaserin in terms of risk of new-onset diabetes.

SUBMITTER: Moura FA 

PROVIDER: S-EPMC11410501 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature